|Articles|January 19, 2021
Screening developability and pre-formulation by HT-DLS
Author(s)Wyatt Technology
Assessing a drug candidate early in discovery and development minimizes the risk of costly downstream failure. This white paper illustrates the application of automated DLS for aggregation and stability investigations.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
VectorY Doses First Patient in TDP-43–Targeting ALS Trial
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Women in STEM: Building Sustainable Cost and Access Models for Advanced Therapies (Part 1)
4
Ivonescimab Breakthrough Designation Highlights Progress in BTC Treatment
5